Free Trial

INmune Bio (INMB) Competitors

INmune Bio logo
$2.36 +0.27 (+12.92%)
Closing price 04:00 PM Eastern
Extended Trading
$2.22 -0.15 (-6.14%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

INMB vs. ALT, CDTX, KROS, RLAY, DNTH, ARVN, MRVI, TSHA, OPT, and TYRA

Should you be buying INmune Bio stock or one of its competitors? The main competitors of INmune Bio include Altimmune (ALT), Cidara Therapeutics (CDTX), Keros Therapeutics (KROS), Relay Therapeutics (RLAY), Dianthus Therapeutics (DNTH), Arvinas (ARVN), Maravai LifeSciences (MRVI), Taysha Gene Therapies (TSHA), Opthea (OPT), and Tyra Biosciences (TYRA). These companies are all part of the "pharmaceutical products" industry.

INmune Bio vs. Its Competitors

INmune Bio (NASDAQ:INMB) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment.

INmune Bio has higher earnings, but lower revenue than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INmune Bio$10K5,564.88-$42.08M-$1.93-1.22
Altimmune$20K19,871.95-$95.06M-$1.26-3.89

In the previous week, INmune Bio had 15 more articles in the media than Altimmune. MarketBeat recorded 37 mentions for INmune Bio and 22 mentions for Altimmune. Altimmune's average media sentiment score of 0.23 beat INmune Bio's score of -0.25 indicating that Altimmune is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
INmune Bio
1 Very Positive mention(s)
3 Positive mention(s)
20 Neutral mention(s)
8 Negative mention(s)
1 Very Negative mention(s)
Neutral
Altimmune
4 Very Positive mention(s)
3 Positive mention(s)
9 Neutral mention(s)
5 Negative mention(s)
0 Very Negative mention(s)
Neutral

INmune Bio currently has a consensus price target of $18.40, indicating a potential upside of 679.66%. Altimmune has a consensus price target of $19.00, indicating a potential upside of 287.76%. Given INmune Bio's higher possible upside, equities research analysts plainly believe INmune Bio is more favorable than Altimmune.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INmune Bio
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.57
Altimmune
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.00

12.7% of INmune Bio shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 35.7% of INmune Bio shares are held by company insiders. Comparatively, 4.1% of Altimmune shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

INmune Bio has a net margin of 0.00% compared to Altimmune's net margin of -451,200.00%. Altimmune's return on equity of -65.44% beat INmune Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
INmune BioN/A -119.35% -89.37%
Altimmune -451,200.00%-65.44%-58.43%

INmune Bio has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Comparatively, Altimmune has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500.

Summary

Altimmune beats INmune Bio on 9 of the 16 factors compared between the two stocks.

Get INmune Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INMB vs. The Competition

MetricINmune BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$49.29M$2.88B$5.54B$8.87B
Dividend YieldN/A2.64%5.39%4.10%
P/E Ratio-1.2221.3126.1719.90
Price / Sales5,564.88278.47414.67113.66
Price / CashN/A41.4736.1356.90
Price / Book1.637.518.055.38
Net Income-$42.08M-$55.05M$3.15B$248.50M
7 Day Performance-67.98%2.45%1.85%2.97%
1 Month Performance-67.18%7.33%4.81%6.02%
1 Year Performance-70.76%5.38%34.86%20.39%

INmune Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INMB
INmune Bio
1.5849 of 5 stars
$2.36
+12.9%
$18.40
+679.7%
-75.2%$49.29M$10K-1.2210Trending News
Analyst Downgrade
High Trading Volume
ALT
Altimmune
2.2959 of 5 stars
$6.99
-0.6%
$19.00
+171.8%
-41.3%$566.94M$20K-5.5550
CDTX
Cidara Therapeutics
4.1313 of 5 stars
$44.95
+113.8%
$45.43
+1.1%
+307.2%$564.12M$1.27M-1.5390Analyst Forecast
Insider Trade
Gap Down
High Trading Volume
KROS
Keros Therapeutics
4.1436 of 5 stars
$13.76
+2.0%
$30.56
+122.1%
-69.5%$558.86M$214.71M-76.44100Positive News
RLAY
Relay Therapeutics
3.0479 of 5 stars
$3.23
+1.3%
$17.67
+447.0%
-45.0%$553.77M$7.68M-1.45330Positive News
DNTH
Dianthus Therapeutics
1.454 of 5 stars
$17.20
+2.1%
$53.00
+208.1%
-37.8%$553.15M$6.24M-5.9780News Coverage
Analyst Forecast
Gap Up
ARVN
Arvinas
3.7229 of 5 stars
$7.40
-0.5%
$20.29
+174.2%
-70.6%$540.13M$426.90M-11.21420Positive News
MRVI
Maravai LifeSciences
3.6251 of 5 stars
$2.11
+2.4%
$6.64
+214.6%
-63.8%$537.33M$259.18M-1.85610
TSHA
Taysha Gene Therapies
3.3812 of 5 stars
$2.49
+1.2%
$7.57
+204.1%
+3.5%$534.51M$7.22M-7.32180Analyst Forecast
OPT
Opthea
0.5023 of 5 stars
$3.41
+7.2%
$1.33
-60.9%
+78.5%$524.83M$120K0.008News Coverage
Positive News
Gap Up
TYRA
Tyra Biosciences
1.9387 of 5 stars
$9.71
+5.2%
$30.83
+217.5%
-43.8%$515.50MN/A-5.9620News Coverage
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:INMB) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners